M. Worbes-Cerezo

Health Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries

◾ Type 2 diabetes (T2D) is a leading cause of cardiovascular disorders, blindness, renal failure, and amputations, and is associated with an increased risk of numerous other medical problems1 ◾ Weight control is a cornerstone of T2D management, and is included in the joint treatment guidelines from the American Diabetes Association and European Association for the Study of Diabetes1 ◾ Previous studies have demonstrated the benefits of weight loss on glycaemic control,2 but the impact of weight loss on patient-reported outcomes among patients in Europe with T2D is not widely reported ◾ The current study was conducted to describe the association between changes in weight and healthrelated quality of life (hRQoL), work productivity and activity impairment, and health care use in European adults with T2D who are taking steps to lose weight

The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland

were sourced from the literature. Both costs and outcomes were discounted at 5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in Ireland. Sensitivity analyses suggest that these results are robust. ConClusions: These simulations suggest that the use of canagliflozin in patients in need of additional glycaemic control in dual, triple and add-on to insulin lines of therapy is a more efficient use of health care funds than the use of sitagliptin in the Irish setting.